Phase I trial of adjuvant chemotherapy with modified S-1 and propagermanium for pancreatic cancer

Phase I trial of adjuvant chemotherapy with modified S-1 and propagermanium for pancreatic cancer - Phase I trial of adjuvant chemotherapy with modified S-1 and propagermanium for pancreatic cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017715

Enrollment

Registered

2015-07-01

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

TS-1 &lt

1.25m2, 80mg/body 1.25m2&lt

and&lt

1.5m2, 100mg/body 1.5m2&lt

, 120mg/body day1-28, q2w, x6 propagerumanium 30mg/day day1-28, q2w, x6

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically proven pancreatic adenocarcinoma 2)Gross complete resection (R0) 3)Age above 20 years 4)Status of 0 or 1 5)Adequate hematologic, hepatic and renal function 6)Good oral intake 7)Start therapy after operation within 4 weeks later and 12 weeks 8)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Non curative operation 2)Active concomitant malignancy 3)History of severe anaphylaxies 4)Severe complications, such as heart failure, renal failure, liver failure, watery diarrhea, paresis of intestine, ileus and severe diabetes mellitus 5)With the jaundice or cirrhosis 6)Active infection 7)Pregnant or pregnant possibility 8)Severe mental disorder 9)Inappropriate

Design outcomes

Primary

Measure	Time frame
safety	—

Countries

Japan

Contacts

Public ContactDaisaku Yamada

Osaka University Hospital Division of HBP surgery and Transplantation

dyamada@gesurg.med.osaka-u.ac.jp06-6879-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026